Ocugen Competitors

Adaptive Biotechnologies (NASDAQ:ADPT) and Ocugen (NASDAQ:OCGN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation.

Institutional & Insider Ownership

80.8% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 8.5% of Ocugen shares are owned by institutional investors. 22.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 3.5% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Adaptive Biotechnologies and Ocugen, as reported by MarketBeat.

Adaptive Biotechnologies presently has a consensus price target of $61.40, indicating a potential upside of 40.57%. Ocugen has a consensus price target of $4.80, indicating a potential downside of 46.49%. Given Adaptive Biotechnologies' higher possible upside, research analysts plainly believe Adaptive Biotechnologies is more favorable than Ocugen.

Earnings & Valuation

This table compares Adaptive Biotechnologies and Ocugen's revenue, earnings per share (EPS) and valuation.

Ocugen has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Adaptive Biotechnologies has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.56, suggesting that its stock price is 256% more volatile than the S&P 500.

Profitability

This table compares Adaptive Biotechnologies and Ocugen's net margins, return on equity and return on assets.

Summary

Adaptive Biotechnologies beats Ocugen on 8 of the 13 factors compared between the two stocks.

Twist Bioscience (NASDAQ:TWST) and Ocugen (NASDAQ:OCGN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation.

Institutional & Insider Ownership

87.9% of Twist Bioscience shares are owned by institutional investors. Comparatively, 8.5% of Ocugen shares are owned by institutional investors. 7.0% of Twist Bioscience shares are owned by company insiders. Comparatively, 3.5% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Twist Bioscience and Ocugen, as reported by MarketBeat.

Twist Bioscience presently has a consensus price target of $133.3333, indicating a potential upside of 14.33%. Ocugen has a consensus price target of $4.80, indicating a potential downside of 46.49%. Given Twist Bioscience's higher possible upside, research analysts plainly believe Twist Bioscience is more favorable than Ocugen.

Earnings & Valuation

This table compares Twist Bioscience and Ocugen's revenue, earnings per share (EPS) and valuation.

Ocugen has lower revenue, but higher earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Twist Bioscience has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.56, suggesting that its stock price is 256% more volatile than the S&P 500.

Profitability

This table compares Twist Bioscience and Ocugen's net margins, return on equity and return on assets.

Summary

Ocugen beats Twist Bioscience on 8 of the 13 factors compared between the two stocks.

Halozyme Therapeutics (NASDAQ:HALO) and Ocugen (NASDAQ:OCGN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Halozyme Therapeutics and Ocugen, as reported by MarketBeat.

Halozyme Therapeutics presently has a consensus price target of $42.9167, indicating a potential upside of 6.20%. Ocugen has a consensus price target of $4.80, indicating a potential downside of 46.49%. Given Halozyme Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Halozyme Therapeutics is more favorable than Ocugen.

Institutional & Insider Ownership

98.5% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 8.5% of Ocugen shares are owned by institutional investors. 2.6% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Halozyme Therapeutics and Ocugen's net margins, return on equity and return on assets.

Risk and Volatility

Halozyme Therapeutics has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.56, suggesting that its stock price is 256% more volatile than the S&P 500.

Earnings & Valuation

This table compares Halozyme Therapeutics and Ocugen's revenue, earnings per share (EPS) and valuation.

Ocugen has lower revenue, but higher earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Summary

Halozyme Therapeutics beats Ocugen on 10 of the 13 factors compared between the two stocks.

Ocugen (NASDAQ:OCGN) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.

Analyst Ratings

This is a summary of recent ratings and price targets for Ocugen and Vir Biotechnology, as reported by MarketBeat.

Ocugen currently has a consensus target price of $4.80, indicating a potential downside of 46.49%. Vir Biotechnology has a consensus target price of $63.8571, indicating a potential upside of 60.97%. Given Vir Biotechnology's higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than Ocugen.

Institutional & Insider Ownership

8.5% of Ocugen shares are owned by institutional investors. Comparatively, 54.5% of Vir Biotechnology shares are owned by institutional investors. 3.5% of Ocugen shares are owned by company insiders. Comparatively, 37.2% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Ocugen and Vir Biotechnology's net margins, return on equity and return on assets.

Volatility & Risk

Ocugen has a beta of 3.56, meaning that its stock price is 256% more volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of -0.99, meaning that its stock price is 199% less volatile than the S&P 500.

Earnings and Valuation

This table compares Ocugen and Vir Biotechnology's revenue, earnings per share and valuation.

Ocugen has higher earnings, but lower revenue than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Summary

Ocugen beats Vir Biotechnology on 7 of the 13 factors compared between the two stocks.

Ocugen (NASDAQ:OCGN) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.

Earnings and Valuation

This table compares Ocugen and Kodiak Sciences' revenue, earnings per share and valuation.

Kodiak Sciences is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Ocugen and Kodiak Sciences, as reported by MarketBeat.

Ocugen currently has a consensus target price of $4.80, indicating a potential downside of 46.49%. Kodiak Sciences has a consensus target price of $129.1818, indicating a potential upside of 15.68%. Given Kodiak Sciences' higher probable upside, analysts plainly believe Kodiak Sciences is more favorable than Ocugen.

Profitability

This table compares Ocugen and Kodiak Sciences' net margins, return on equity and return on assets.

Institutional & Insider Ownership

8.5% of Ocugen shares are owned by institutional investors. Comparatively, 82.3% of Kodiak Sciences shares are owned by institutional investors. 3.5% of Ocugen shares are owned by company insiders. Comparatively, 39.3% of Kodiak Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Ocugen has a beta of 3.56, meaning that its stock price is 256% more volatile than the S&P 500. Comparatively, Kodiak Sciences has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500.

Summary

Kodiak Sciences beats Ocugen on 6 of the 10 factors compared between the two stocks.

Ocugen (NASDAQ:OCGN) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Ocugen and Iovance Biotherapeutics' top-line revenue, earnings per share (EPS) and valuation.

Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Ocugen and Iovance Biotherapeutics, as reported by MarketBeat.

Ocugen currently has a consensus target price of $4.80, suggesting a potential downside of 46.49%. Iovance Biotherapeutics has a consensus target price of $50.10, suggesting a potential upside of 57.70%. Given Iovance Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Ocugen.

Profitability

This table compares Ocugen and Iovance Biotherapeutics' net margins, return on equity and return on assets.

Institutional and Insider Ownership

8.5% of Ocugen shares are held by institutional investors. Comparatively, 94.6% of Iovance Biotherapeutics shares are held by institutional investors. 3.5% of Ocugen shares are held by insiders. Comparatively, 9.9% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Ocugen has a beta of 3.56, meaning that its share price is 256% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

Summary

Ocugen beats Iovance Biotherapeutics on 6 of the 11 factors compared between the two stocks.